IASLC World Conference on Lung Cancer

A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

Recent study results demonstrated that an at-home prehabilitation program may improve surgical outcomes in patients with lung cancer.

A survey conducted by the LUNGevity Foundation determined that 96% of patients with lung cancer felt that they were concerned about the COVID-19 pandemic affecting their treatment.

New study results demonstrate that patients with lung cancer have experienced more worries and general distress during the COVID-19 pandemic compared to other patients with cancer.

Despite offering an increased number of services to patients, the decrease in funding as a result of the pandemic has put a strain on patient advocacy and support organizations around the world, leaving many, particularly those that specialize in the support of patients with lung cancer, in urgent need of financial support to continue to meet the increased need.

Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer.

Onivyde may offer patients with small cell lung cancer whose disease has progressed after initial chemotherapy a new treatment option, according to updated study results.

Treatment with immuno-oncology therapies induces better responses in younger patients with small cell lung cancer, compared to older patients.

Though there are currently few approved treatments for advanced, pre-treated small cell lung cancer (SCLC), this patient population may have a safe and effective new option in apatinib, according to updated data from a prospective phase 2 study.

In a survey conducted by the Cancer Support Community, 33% of patients with lung cancer reported they were somewhat or not at all involved in the decision-making process, and 66% were not as knowledgeable about their treatment options as needed to make this decision.